

LIST OF CONTENTS

NUMBER 1

This issue's topics
(see after contents pages)

News		1
Editorial Comments		
	'Onco-tourism'—season ticket, anyone? <i>J.F. Smyth</i>	7
	EUROCARE <i>J.R. Mann</i>	8
Reviews		
	The role of protein kinase C- α (PKC- α) in malignancies of the gastrointestinal tract <i>M. Lahm, B.M. Paterson, K. Sundell and D. Ma</i>	10
	RNA polymerase III transcription—a battleground for tumour suppressors and oncogenes <i>R.J. White</i>	21
Clinical Oncology		
	Invariant p53 immunostaining in primary and recurrent breast cancer <i>S.M. Poelman, R. Heimann, G.F. Fleming, W.M. Recant and S.D. Conzen</i>	28
	Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment <i>B. Linderholm, J. Andersson, B. Lindh, L. Beckman, M. Erlanson, K. Edin, B. Tavelin, K. Granqvist and R. Henriksson</i>	33
	Cognitive dysfunction and subjective complaints of cancer patients: a cross-sectional study in a cancer rehabilitation centre <i>M. Poppelreuter, J. Weis, A.K. Külz, O. Tucha, K.W. Lange and H.H. Bartsch</i>	43
	HER2 and COX2 expression in human prostate cancer <i>J. Edwards, R. Mukherjee, A.F. Munro, A.C. Wells, A. Almushatat and J.M.S. Bartlett</i>	50
	HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? <i>Z. Latif, A.D. Watters, I. Dunn, K. Grigor, M.A. Underwood and J.M.S. Bartlett</i>	56
	Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival: a validation study <i>M. Holten-Andersen, I.J. Christensen, M. Nilbert, P.O. Bendahl, H.J. Nielsen, N. Brünner and E. Fernebro</i>	64
Paediatric Oncology		
	Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992 <i>G. Bacci, C. Forni, A. Longhi, S. Ferrari, D. Donati, M. De Paolis, E. Barbieri, P. Pignotti, P. Rosito and M. Versari</i>	73
Epidemiology and Cancer Prevention		
	Serum enterolactone levels and the risk of breast cancer in women with palpable cysts <i>F. Boccardo, G. Lunardi, P. Guglielmini, M. Parodi, R. Murialdo, G. Schettini and A. Rubagotti</i>	84
	Familial clustering of ovarian and endometrial cancers <i>K. Hemminki and C. Granström</i>	90

List of Contents

	Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries <i>F. Bray, J.E. Tyczynski and D.M. Parkin</i>	96
	Inequalities in lung cancer mortality by the educational level in 10 European populations <i>J.P. Mackenbach, M. Huisman, O. Andersen, M. Bopp, J.-K. Borgan, C. Borrell, G. Costa, P. Deboosere, A. Donkin, Sylvie Gadeyne, C. Minderi, E. Regidor, T. Spadea, T. Valkonen and A.E. Kunst</i>	126
Experimental Oncology	Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas <i>C.J. Kim, Y.G. Cho, J.Y. Park, T.Y. Kim, J.H. Lee, H.S. Kim, J.W. Lee, Y.H. Song, S.W. Nam, S.H. Lee, N.J. Yoo, J.Y. Lee and W.S. Park</i>	136
	Uptake of 5-fluorouracil (5-FU) in peritoneal metastases in relation to the route of drug administration and tumour debulking surgery: an autoradiographic study in the rat <i>H. Mahteme, B. Larsson, A. Sundin, H. Khamis and W. Graf</i>	142
	Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells <i>A. David, P. Kopečková, T. Minko, A. Rubinstein and J. Kopeček</i>	148
	Model for paraaortic lymph node metastasis produced by orthotopic implantation of ovarian carcinoma cells in athymic nude mice <i>Y. Tamada, D. Aoki, S. Nozawa and T. Irimura</i>	158
Announcement		164
Calendar of Forthcoming Meetings		I
NUMBER 2		
	This issue's topics (see after contents pages)	
News		165
Editorial Comment		
	The future of clinical cancer research: who's teaching the next generation? The Flims-Vail model <i>C. Palmieri, S. Wanaski, J. Panse and B. Medeiros</i>	173
Debate: The Role of Sentinel Node Biopsy in Breast Cancer?		
	Preoperative ultrasound-guided node biopsy and sentinel node augmented node sample is best practice <i>R.D. Macmillan, R.S. Rampaul, S. Lewis and A.J. Evans</i>	176
	Implications of lymphatic mapping for staging and adjuvant treatment of patients with breast cancer <i>O.E. Nieweg and H. Bartelink</i>	179
	Sentinel node procedure in breast carcinoma: a valid tool to omit unnecessary axillary treatment or even more? <i>E.J.T. Rutgers</i>	182
Review		
	Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials <i>F. Efficace, A. Bottomley, V. Vanvoorden and J.M. Blazeby</i>	187

Clinical Oncology

Adherence to the guidelines of the CCCE in the treatment of node-positive breast cancer patients <i>P.B. Ottevanger, P.H.M. De Mulder, R.P.T.M. Grol, H. van Lier and L.V.A.M. Beex</i>	198
Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy <i>T. Petit, M. Wilt, M. Velten, R. Millon, J.-F. Rodier, C. Borel, R. Mors, P. Haegelé, M. Eber and J.-P. Ghassia</i>	205
Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lympho-nodectomy and early excision of their nodal disease <i>L. Kretschmer, R. Hilgers, M. Möhrle, B.R. Balda, H. Breuninger, B. Konz, C. Kunte, W.C. Marsch, C. Neumann and H. Starz</i>	212
Preoperative chemoradiotherapy <i>versus</i> preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group <i>J.F. Bosset, G. Calais, A. Daban, C. Berger, L. Radosevic-Jelic, P. Maingon, E. Bardet, M. Pierart, A. Briffaux and for the EORTC Radiotherapy Group</i>	219
The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are: palliative chemotherapy and watchful-waiting <i>C.G. Koedoot, F.J. Oort, R.J. de Haan, P.J.M. Bakker, A. de Graeff and J.C.J.M. de Haes</i>	225

Paediatric Oncology

Immunity against vaccine-preventable potentially neurotropic diseases in children treated for malignant brain tumours with HIT-91 chemo- and radiotherapy <i>E. Schuller, E. Förster-Waldl, I. Slavec and W. Maurer</i>	236
--	-----

Epidemiology and
Cancer Prevention

Predictive value of rectal bleeding for distal colonic neoplastic lesions in a screened population <i>R. Ferraris, C. Senore, M. Fracchia, S. Sciallero, L. Bonelli, W.S. Atkin, N. Segnan and the SCORE Working Group, Italy</i>	245
Association of brain tumours with other neoplasms in families <i>K. Hemminki and X. Li</i>	253
Cancer aggregation and complex segregation analysis of families with female non-smoking lung cancer probands in Taiwan <i>P.-F. Wu, C.-H. Lee, M.-J. Wang, W.B. Goggins, T.-A. Chiang, M.-S. Huang and Y.-C. Ko</i>	260

Experimental
Oncology

Smad2 suppresses the growth of Mv1Lu cells subcutaneously inoculated in mice <i>T. Sjöblom, I. Yakymovych, C.-H. Heldin, A. Östman and S. Souchevnytskyi</i>	267
Prevalence of liver tumours in HIV-1 <i>tat</i> -transgenic mice treated with urethane <i>G. Altavilla, A. Caputo, C. Trabanelli, E. Brocca Cofano, S. Sabbioni, M.A. Menegatti, G. Barbanti-Brodano and A. Corallini</i>	275
Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence <i>H. Wildiers, B. Ahmed, G. Guetens, G. De Boeck, E.A. de Bruijn, W. Landuyt and A.T. van Oosterom</i>	284
Improved targeting of platinum chemotherapeutics: the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models <i>X. Lin, Q. Zhang, J.R. Rice, D.R. Stewart, D.P. Norwotnik and S.B. Howell</i>	291

	Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas <i>I. Fichtner, W. Slisow, J. Gill, M. Becker, B. Elbe, T. Hillebrand and M. Bibby</i>	298
Calendar of Forthcoming Meetings		I
NUMBER 3		
	This issue's topics (see after contents pages)	
News		309
Editorial Comment		
	Behavioural and social science research in cancer: time for action <i>D. Weller</i>	314
Current Perspective		
	Research in the behavioural and social sciences to improve cancer control and care: a strategy for development <i>A report of an Expert Group</i>	316
Review		
	Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications <i>H. Brenner, O. Gefeller and T. Hakulinen</i>	326
Clinical Oncology		
	Wide metastatic spreading in infiltrating lobular carcinoma of the breast <i>S. Ferlicot, A. Vincent-Salomon, J. Médioni, P. Genin, C. Rosty, B. Sigal-Zafrani, P. Fréneaux, M. Jouve, J.-P. Thiery and X. Sastre-Garau</i>	336
	The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile <i>M.-C. Mathieu, R. Rouzier, A. Llombart-Cussac, L. Sideris, S. Koscielny, J.P. Travagli, G. Contesso, S. Delaloge and M. Spielmann</i>	342
	Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial <i>A.J. ten Tije, C.H. Smorenburg, C. Seynaeve, A. Sparreboom, K.L.C. Schothorst, L.G.M. Kerkhofs, L.G.P.M. van Reizen, G. Stoter, M. Bontenbal and J. Verweij</i>	352
	Selective immunohistochemical staining shows significant prognostic influence of lymphatic and blood vessels in patients with malignant melanoma <i>J. Valencak, E. Heere-Ress, T. Kopp, S.F. Schoppmann, H. Kittler and H. Pehamberger</i>	358
	Preoperative psychological reactions and quality of life among women with an increased risk of breast cancer who are considering a prophylactic mastectomy <i>Y. Brandberg, B. Arver, A. Lindblom, K. Sandelin, M. Wickman and P. Hall</i>	365
	'State of the art' of radical hysterectomy; current practice in European oncology centres <i>J.B. Trimbos, M. Franchi, F. Zanaboni, J.v.d. Velden and I. Vergote</i>	375
	Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment <i>E. Shmueli, N. Wigler and M. Inbar</i>	379

	Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine <i>T. Robak, J.Z. Blonski, J. Gora-Tybor, M. Kasznicki, L. Konopka, B. Ceglarek, M. Komarnicki, K. Lewandowski, A. Hellmann, K. Lewandowski, A. Moskwa, A. Dmoszynska, B. Sokolowska, A. Dwilewicz-Trojaczek, A. Tomaszewska, A. Sulek and M. Calbecka</i>	383
	Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-2b <i>versus</i> rIFN- <i>versus</i> ISCADOR M® <i>versus</i> observation after surgery in melanoma patients with either high-risk primary (thickness>3 mm) or regional lymph node metastasis <i>U.R. Kleeberg, S. Suci, E.B. Bröcker, D.J. Ruiter, C. Chartier, D. Liénard, J. Marsden, D. Schadendorf, A.M.M. Eggermont for the EORTC Melanoma Group in cooperation with the German Cancer Society (DKG)</i>	390
	The oral NK ₁ antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials <i>R. de Wit, J. Herrstedt, B. Rapoport, A.D. Carides, J. Guoguang-Ma, M. Elmer, C. Schmidt, J.K. Evans and K.J. Horgan</i>	403
Paediatric Oncology	Risk-adapted treatment for childhood hepatoblastoma: final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2 <i>G. Perilongo, E. Shafford, R. Maibach, D. Aronson, L. Brugieres, P. Brock, M. Childs, P. Czauderna, G. MacKinlay, J.B. Otte, J. Pritchard, R. Pordelli, M. Scopinaro, C. Staalman and J. Plaschkes</i>	411
Epidemiology and Cancer Prevention	One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden <i>S. Malander, M. Ridderheim, A. Måsbäck, N. Loman, U. Kristoffersson, H. Olsson, M. Nilbert and Å. Borg</i>	422
	Exposure to the sun and sunbeds and the risk of cutaneous melanoma in the UK: a case-control study <i>V. Bataille, A. Winnett, P. Sasieni, J.A. Newton Bishop and J. Cuzick</i>	429
Experimental Oncology	Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers <i>M. Letsch, A.V. Schally, A. Stangelberger, K. Groot and J. L. Varga</i>	436
	Alkaline single-cell gel electrophoresis (comet assay): a simple technique to show genomic instability in sporadic breast cancer <i>S. Collet-Durel, N. Guitton, K. Nourgalieva, F. Legue, J. Lévéque, B. Danic and C. Chenal</i>	445
	Detection of cell-free nucleic acids in bronchial lavage fluid supernatants from patients with lung cancer <i>B. Schmidt, T. Carstensen, E. Engel, B. Jandrig, C. Witt and M. Fleischhacker</i>	452
	Heterogeneity of immunostaining for tumour markers in non-small cell lung carcinoma <i>C. Macdonald, A. Michael, K. Colston and J. Mansi</i>	461
Calendar of Forthcoming Meetings		I
NUMBER 4		
	This issue's topics (see after contents pages)	ix
News		467

Editorial Comment

- Is local control necessarily an indicator of quality? 472
D.A.L. Morgan and J.M. Kurtz

Review

- Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials 474
E.C. Moser, E.M. Noordijk, M. van Glabbeke, I. Teodorovic, C. de Wolf-Peters, P. Carde, J.W. Baars, U. Tirelli, J.M.M. Raemaekers and J.C. Kluin-Nelemans

Clinical Oncology

- Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA 481
G. Sotermos, D. Nielsen, V. Schioler, H. Mouridsen and P. Dombrowsky
- Using loco-regional recurrence as an indicator of the quality of breast cancer treatment 487
M.F. Ernst, A.C. Voogd, J.W. W. Coebergh, P.M. Poortmans and J.A. Roukema
- Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer 494
M.A.A. Al-Rawi, K. Rmali, G. Watkins, R.E. Mansel and W.G. Jiang
- Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection: results of EORTC Translational Research Fund studies 503
R.J. Oliver, R.T.M. Woodward, P. Sloan, N.S. Thakker, I.J. Stratford and R.E. Airley
- Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer 508
M.L. Veronese, J.P. Stevenson, W. Sun, M. Redlinger, K. Algazy, B. Giantonio, S. Hahn, D. Vaughn, C. Thorn, A.S. Whitehead, D.G. Haller and P.J. O'Dwyer
- The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option? 515
Th. Delaunoy, M. Ducreux, V. Boige, C. Dromain, J.-C. Sabourin, P. Duvalard, M. Schlumberger, T. de Baere, P. Rougier, P. Ruffie, D. Elias, P. Lasser and E. Baudin
- Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP) 521
C. Rodary, V. Pezet-Langevin, S. Garcia-Acosta, T. Lesimple, A. Lortholary, M.C. Kaminsky, J. Bennouna, S. Culine, H. Bourgeois and K. Fizazi
- Knowledge of and attitudes toward complementary and alternative therapies: a national multicentre study of oncology professionals in Norway 529
T. Risberg, A. Kolstad, Y. Bremnes, H. Holte, E.A. Wist, O. Mella, O. Klepp, T. Wilsgaard and B.R. Cassileth
- Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer 536
P. Fumoleau, R. Lartigues, C. Clippe, V. Dièras, H. Orfeuvre, T. Lesimple, S. Culine, B. Audhuy, D. Serin, H. Curé, E. Vuillemin, J.-F. Morère, F. Montestruc, Z. Mouri and M. Namer
- Current soft-tissue sarcoma classifications 543
S. Daugaard
- Surgical treatment of pancreatic adenocarcinoma: actual survival and prognostic factors in 343 patients 549
K.F.D. Kuhlmann, S.M.M. de Castro, J.G. Wesseling, F.J.W. ten Kate, G.J.A. Offerhaus, O.R.C. Busch, T.M. van Gulik, H. Obertop and D.J. Gouma
- Endoscopic ultrasound-guided fine-needle aspiration in patients with mediastinal abnormalities and previous extrathoracic malignancy 559
H. Kramer, G.H. Koëter, D.T. Sleijfer, J.W.G. van Putten and H.J.M. Groen
- Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin 563
C. Sessa, A. Perotti, E. Salvatorelli, G. Minotti, L. Viganò, A. Lladò, G. Capri, A. Locatelli, S. Colombini, F. Peccatori, M. Voi, S. Marsoni and L. Gianni

Paediatric Oncology

- Severity of enterocolitis is predicted by IL-8 in paediatric oncology patients 571
M.D. van de Wetering, H.N. Caron, M. Biezeveld, J.A.J.M. Taminau, F.J. ten Kate, L. Spanjaard and T.W. Kuijpers

Epidemiology and
Cancer Prevention

- Medically recorded allergies and the risk of childhood acute lymphoblastic leukaemia 579
L. Spector, F. Groves, F. DeStefano, J. Liff, M. Klein, J. Mullooly, S. Black, H. Shinefield, J. Ward, M. Marcy and the Vaccine Safety Datalink Project
- Little or no space-time clustering found amongst cases of childhood lymphoma in North West England 585
R.J.Q. McNally, F.E. Alexander, O.B. Eden and J.M. Birch
- Contraceptive methods and induced abortions and their association with the risk of colon cancer in Shanghai, China 590
K.A. Rosenblatt, D. Li, Gao, R.M. Ray, Z.C. Nelson and D.B. Thomas

Experimental
Oncology

- Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy 594
J. Walker, C. Martin and R. Callaghan
- Inhibition of multidrug resistance by immunisation with synthetic P-glycoprotein-derived peptides 606
C. Pawlak-Roblin, P.-F. Tosi, L. Perrin, J. Devy, L. Venteo, P. Albert, C. Nicolau and C. Madoulet
- PGP9.5 mRNA could contribute to the molecular-based diagnosis of medullary thyroid carcinoma 614
T. Takano, A. Miyauchi, F. Matsuzuka, H. Yoshida, Y. Nakata, K. Kuma and N. Amino

Letters

- Comment on “The process of metastatisation for breast cancer” by J. Engel, R. Eckel, J. Kerr *et al.* 619
R. Demicheli and M.W. Retsky
- Response to comments on “The process of metastatisation for breast cancer” by J. Engel, R. Eckel, J. Kerr *et al.* 621
J. Engel, H. Sauer, D. Hölzel, G. Fürstenberger and H.-J. Senn
- Where to next with extracranial rhabdoid tumours in children 624
B.M.D. Brennan, A.B.M. Foot, C. Stiller, A. Kelsey, G. Vujanic, R. Grundy, K. Pritchard Jones on behalf of the United Kingdom Children’s Cancer Study Group (UKCCSG)

Errata

- Erratum to “Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients: 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin”: [European Journal of Cancer, 39 (2003) 1129–1140] 627
Ch. Dittrich, P. Sevela, H. Salzer, A. Obermair, P. Speiser, G. Breiteneker, M. Schemper, A. Kaider on behalf of the Austrian Ovarian Cancer Study Group
- Erratum to “Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust” [European Journal of Cancer, 39 (2003) 1818–1827] 628
F. Balkwill, R.C. Bast, Jr, J. Berek, G. Chenevix-Trench, M. Gore, T. Hamilton, I. Jacobs, G. Mills, R. Souhami, N. Urban, S. Orsulic and J. Smyth

Calendar of
Forthcoming
Meetings

I

NUMBER 5

This issue's topics
(see after contents pages)

News 629

Editorial Comments

Cancer registries contribute to quality improvements in clinical care for all European cancer patients 635
R. Sankila and J.W. Coebergh

Colorectal cancer screening in Europe: first things first 638
J.W.W. Coebergh

Review

Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review 643
E.C. van Dalen, H.J.H. van der Pal, P.J.M. Bakker, H.N. Caron and L.C.M. Kremer

Guidelines

Guidelines for the management of women at increased familial risk of breast cancer 653
P. Sauven on behalf of the Association of Breast Surgery Family History Guidelines Panel

Clinical Oncology

Announcement

Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer: a phase II trial of the EORTC-New Drug Development Group 666
G. Giaccone, E.F. Smit, M. de Jonge, E. Dansin, E. Briasoulis, A. Ardizzoni, J.-Y. Douillard, D. Spaeth, D. Lacombe, B. Baron, P. Bachmann, P. Fumoleau for the EORTC-New Drug Development Group

Age-specific detriments to quality of life among breast cancer patients one year after diagnosis 673
V. Arndt, H. Merx, T. Stürmer, C. Stegmaier, H. Ziegler and H. Brenner

Real-time pharmacokinetics guiding clinical decisions: phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours 681
O. Soepenberg, A. Sparreboom, M.J.A. de Jonge, A. S. Th. Planting, G. de Heus, W.J. Loos, C.M. Hartman, C. Bowden and J. Verweij

Use of c-KIT/PDGFR α mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group 689
M. Debiec-Rychter, H. Dumez, I. Judson, B. Wasag, J. Verweij, M. Brown, S. Dimitrijevic, R. Sciot, M. Stul, H. Vranck, M. Scurr, A. Hagemeijer, M. Van Glabbeke and A. T. van Obsterom

Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy: cardiovascular risk factors and signs of vascular damage 696
F.Y.F.L. de Vos, J. Nuver, P.H.B. Willemse, A.G.J. van der Zee, J. Messerschmidt, J.G.M. Burgerhof, E.G.E. de Vries and J.A. Gietema

Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer 701
J. Nuver, A.J. Smit, D. Th. Sleijfer, A.I. van Gessel, A.M. van Roon, J. van der Meer, M.P. van den Berg, J.G.M. Burgerhof, H.J. Hoekstra, W.J. Sluiter and J.A. Gietema

Paediatric Oncology

Paediatric Update

FLT3 Inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer 707
P. Brown and D. Small

	Commentary	722
	<i>G. Tallen and G. Henze</i>	
	Pathology review for paediatric non-Hodgkin's lymphoma patients in Japan: a report from the Japan association of childhood leukaemia study (JACLS)	725
	<i>A. Nakagawa, S. Nakamura, H. Nakamine, T. Yoshino, T. Takimoto, K. Horibe and K. Ueda</i>	
Epidemiology and Cancer Prevention		
	Colorectal cancer survival trends in Norway 1958–1997	734
	<i>E. Angell-Andersen, S. Tretli, M.P. Coleman, F. Langmark and T. Grotmol</i>	
	Improvements in survival for women with breast cancer in Scotland between 1987 and 1993: impact of earlier diagnosis and changes in treatment	743
	<i>C.S. Thomson, D.H. Brewster, J.A. Dewar, C.J. Twelves on behalf of the Scottish Cancer Therapy Network</i>	
	Family history of benign thyroid disease and cancer and risk of thyroid cancer	754
	<i>A. Memon, A. Berrington de González, Y. Luqmani and A. Suresh</i>	
Experimental Oncology		
	Differential expression of retinoic acid receptor beta (RAR β) and the AP-1 transcription factor in normal, premalignant and malignant human laryngeal tissues	761
	<i>M.V. Karamouzis, G. Sotiropoulou-Bonikou, G. Vondoros, I. Varakis and A.G. Papavassiliou</i>	
	Comment on “The relative contributions of screen-detected <i>in-situ</i> and invasive breast carcinomas in reducing mortality from the disease” by S.W. Duffy, L. Tabar, B. Vitak <i>et al.</i>	774
	<i>A.C. Voogd and M.F. Ernst</i>	
	Reply to comment on “The relative contributions of screen-detected <i>in situ</i> and invasive breast carcinomas in reducing mortality from the disease” by A.C.Voogd, M.F. Ernst	776
	<i>S.W. Duffy, L. Tabar and R.A. Smith</i>	
Letter		
	Modification of SAS macros for a more efficient analysis of relative survival rates	778
	<i>V. Arndt, M. Talbäck, O. Gefeller, T. Hakulinen and H. Brenner</i>	
Errata		
	Erratum to “Role of imprint cytology in the intraoperative evaluation of sentinel lymph nodes for malignant melanoma” [European Journal of Cancer, 39 (2003) 2173–2178]	780
	<i>M. Hočevát, M. Bracko, A. Pogacnik, B. Videgar-Kralj, N. Besic and J.J. Zgajnar</i>	
	Erratum to “The effect of immediate breast reconstruction on adjuvant chemotherapy” [EJC Supplements 1 (2003) 41]	781
	<i>C.W. Taylor and S. Kumar</i>	
Calendar of Forthcoming Meetings		I

NUMBER 6

Special Issue on Preclinical Models in Cancer Drug Discovery and Development*Guest Editors: E.A. Sausville, D.R. Newell*

Preclinical models in cancer drug discovery and development	783
---	-----

E.A. Sausville and D.R. Newell

Update on NCI <i>in vitro</i> drug screen utilities	785
---	-----

S.L. Holbeck

List of Contents

<i>In vitro</i> modelling of human tumour behaviour in drug discovery programmes <i>B.C. Baguley and E.S. Marshall</i>	794
Clonogenic assay with established human tumour xenografts: correlation of <i>in vitro</i> to <i>in vivo</i> activity as a basis for anticancer drug discovery <i>H.H. Fiebig, A. Maier and A.M. Burger</i>	802
The hollow fibre model in cancer drug screening: the NCI experience <i>S. Decker, M. Hollingshead, C.A. Bonomi, J.P. Carter and E.A. Sausville</i>	821
“Of mice and men”: values and liabilities of the athymic nude mouse model in anticancer drug development <i>L.R. Kelland</i>	827
Integrating pharmacology and <i>in vivo</i> cancer models in preclinical and clinical drug development <i>J.K. Peterson and P.J. Houghton</i>	837
<i>In vivo</i> models for endocrine-dependent breast carcinomas: special considerations of clinical relevance <i>I. Fichtner, M. Becker, R. Zeisig and A. Sommer</i>	845
Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages <i>M.C. Bibby</i>	852
Spontaneous and genetically engineered animal models: use in preclinical cancer drug development <i>K. Hansen and C. Khanna</i>	858
Modelling approaches for angiogenesis <i>G. Taraboletti and R. Giavazzi</i>	881
A potential role for imaging technology in anticancer efficacy evaluations <i>M.G. Hollingshead, C.A. Bonomi, S.D. Borgel, J.P. Carter, R. Shoemaker, G. Melillo and E.A. Sausville</i>	890
The Cancer Research UK experience of preclinical toxicology studies to support early clinical trials with novel cancer therapies <i>D.R. Newell, J. Silvester, C. McDowell and S.S. Burtles</i>	899
Multi-species toxicology approaches for oncology drugs: the US perspective <i>J.E. Tomaszewski</i>	907

NUMBER 7

News Obituary Editorial Comments Position Paper	This issue's topics (see after contents pages) Professor Carl Gottfried Schmidt <i>D.K. Hossfeld</i> Cognitive deficits in patients with multisystem Langerhans cell histiocytosis—a commentary <i>R.M. Egeler</i> In relation to Anninga et al.: Overexpression of the <i>HER-2</i> oncogene does not play a role in high-grade osteosarcomas <i>I. Judson</i> The surgical management of elderly cancer patients: recommendations of the SIOG surgical task force <i>R.A. Audisio, F. Bozzetti, R. Gennari, M.T. Jaklitsch, T. Koperna, W.E. Longo, T. Wiggers and A.P. Zbar</i>	915 921 922 924 926
---	---	--

Reviews

Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-florouracil <i>A.B.P. van Kuilenburg</i>	939
--	-----

Physical exercise results in the improved subjective well-being of a few or is effective rehabilitation for all cancer patients?	951
--	-----

L.M. Oldervoll, S. Kaasa, M. J. Hjermstad, J. Å. Lund and J. H. Loge

Clinical Oncology

Overexpression of the <i>HER-2</i> oncogene does not play a role in high-grade osteosarcomas <i>J.K. Aminga, M. J. van de Vijver, A.M. Cleton-Jansen, P.M. P. Kristel, A.H.M. Taminiau, M. Nooij, R.M. Egeler and P.C.W. Hogendoorn</i>	963
--	-----

Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients: analysis of the UK Medical Research Council AML 10 Trial	971
--	-----

M. Watson, G. Buck, K. Wheatley, J.R. Homewood, A.H. Goldstone, J.K.H. Rees and A.K. Burnett

Treatment implications for radiation-induced nausea and vomiting in specific patient groups <i>J.-C. Horiot and M. Aapro</i>	979
---	-----

Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial	988
--	-----

M. Untch, H. Eidtmann, A. du Bois, H.G. Meerpohl, Ch. Thomssen, A. Ebert, N. Harbeck, C. Jackisch, V. Heilman, G. Emons, D. Walkviener, W. Wisese, J.-U. Blohmer, K. Höffken, W. Kuhn, P. Reichardt, M. Muscholl, M. Pauschinger, B. Langer and H. J. Lück

Radiation therapy after breast-serving surgery: first results of a randomised clinical trial in patients with low risk of recurrence	998
--	-----

K.-J. Winzer, R. Sauer, W. Sauerbrei, E. Schmeller, W. Jaeger, M. Braun, J. Dunst, T. Liersch, M. Zedelius, K. Brunnert, H. Guski, C. Schmoor, M. Schumacher for the German Breast Cancer Study Group (GBSG)

Monitoring surgical treatment of screen detected breast lesions in Italy	1006
--	------

V. Distante, M. P. Mano, A. Ponti, L. Cataliotti, L. Filippini, D. Giorgi, M. G. Lazzaretti, C. Marchesi, E. Perfetti, N. Segnan and GISMa Group

Quality of life after brachytherapy in patients with glioblastoma multiforme	1013
--	------

R.W. Koot, K. de Heer, F. J. Oort, M.C.C.M. Hulshof, D.A. Bosch and J.C. J. M. de Haes

Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer	1021
--	------

F. Efficace, L. Biganzoli, M. Piccart, C. Coens, K. Van Steen, T. Cufer, R.E. Coleman, H.A. Calvert, T. Gamucci, C. Twelves, P. Fargeot, A. Bottomley on behalf of EORTC-BCG-IDBBC-NDDG

Paediatric Oncology

Longitudinal assessment of nutritional status in children treated for acute lymphoblastic leukaemia in Cuba	1031
---	------

A. González, L. Cortina, P. González, C. González, T. García and E.G. de Svarch

Paediatric Updates

Oral complications of childhood cancer and its treatment: current best practice <i>P.M. Belfield and A.A. Dwyer</i>	1035
--	------

Commentary <i>V.S. Lucas and G. J. Roberts</i>	1042
---	------

Epidemiology and Cancer Prevention

Lower incidence rates but thicker melanomas in Eastern Europe before 1992: a comparison with Western Europe	1045
---	------

E. de Vries, M. Boniol, J.F. Doré, J.W.W. Coebergh and EUROCARE working group

	Suicide mortality is decreasing among cancer patients in Central Italy <i>G. Miccinesi, E. Crocetti, A. Benvenuti and E. Paci</i>	1053
	Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri <i>T. Luostarinen, M. Lehtinen, T. Bjørge, V. Abeler, M. Hakama, G. Hallmans, E. Jellum, P. Koskela, P. Lenner, A.K. Lie, J. Paavonen, E. Pukkala, P. Saikku, E. Sigstad, S. Thoresen, L.D. Youngman, J. Dillner and T. Hakulinen</i>	1058
Experimental Oncology	An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6 <i>H. Steiner, A. P. Berger, S. Godoy-Tundidor, A. Bjartell, H. Lilja, G. Bartsch, A. Hobisch and Z. Culig</i>	1066
	Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells <i>T. Askund, I. B. Appelskog, O. Ammerpohl, T. J. Ekström and P. M. Almquist</i>	1073
	Distinct patterns of genetic alterations in adenocarcinoma and squamous cell carcinoma of the lung <i>S. M.-H. Sy, N. Wong, T.-W. Lee, G. Tse, T.S.-K. Mok, B. Fan, E. Pang, P. J. Johnson and A. Yim</i>	1082
Letters	Comment on “Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results” by J.-M. Nabholz et al <i>H.T. Mouridsen and H. A. Chaudri-Ross</i>	1095
	Reply to comment on “Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results” by H.T. Mouridsen, H.A. Chaudri-Ross <i>J.-M. Nabholz</i>	1097
Calendar of Forthcoming Meetings		I
	NUMBER 8	
	This issue's topics (see after contents pages)	
News		1099
Editorial Comments	Is breast-conserving therapy in the genetically predisposed breast cancer patient a reasonable and appropriate option? <i>B. G. Haffty and D. Lannin</i>	1105
	Best practice in oral care for children and young people being treated for cancer: can we achieve consensus? <i>F. Gibson</i>	1109
Current Perspective	Breast Cancer Advocacy across Europe through the work and development of EUROPA DONNA, the European Breast Cancer Coalition <i>M. Buchanan, S. Kyriakides, A. Fernandez-Marcos, J. Horvatin, P. Mosconi, D. O'Connell and N. Zernik</i>	1111
Reviews	Childhood adrenocortical tumours <i>R.C. Ribeiro and B. Figueiredo</i>	1117

Clinical Oncology	A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer <i>G. Baaten, A.C. Voogd and J. Wagstaff</i>	1127
	EUROPA DONNA: has strength in its heterogeneity <i>P. Mosconi, M. Buchanan, S. Kyriakides, A. Fernandez-Marcos, J. Horvatin, D. O'Connell, N. Zernik on behalf of EUROPA DONNA</i>	1145
	Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy <i>C. Seynaeve, L.C. Verhoog, L.M.C. van de Bosch, A.N. van Geel, M. Menke-Pluymers, E.J. Meijers-Heijboer, A.M.W. van den Ouweland, A. Wagner, C.L. Creutzberg, M.F. Niermeijer, J.G.M. Klijn and C.T.M. Brekelmans</i>	1150
	A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma: a prospective randomised phase III study <i>M. van Agthoven, C.M. Segeren, I. Buijt, C.A. Uyl-deGroot, B. van der Holt, H.M. Lokhorst and P. Sonneveld</i>	1159
	Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy <i>M.A. Rudek, A. Sparreboom, E.S. Garrett-Mayer, D.K. Armstrong, A.C. Wolff, J. Verweij and S.D. Baker</i>	1170
	S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation <i>K. Arai, T. Teratani, R. Kuruto-Niwa, T. Yamada and R. Nozawa</i>	1179
	Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis: a double-blind, randomised parallel study <i>Y. Minegishi, H. Ohmatsu, T. Miyamoto, S. Niho, K. Goto, K. Kubota, R. Kakimura, S. Kudoh and Y. Nishiwaki</i>	1188
	MAX2—a convenient index to estimate the average per patient risk for chemotherapy toxicity: validation in ECOG trials <i>M. Extermann, M. Bonetti, G.W. Sledge, P.J. O'Dwyer, P. Bonomi and A.B. Benson III</i>	1193
	Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies: 1-year analysis <i>P. Nieboer, E.G.E. de Vries, E. Vellenga, W.T.A. van der Graaf, N.H. Mulder, W.J. Sluiter and J. Th. M. de Wolf</i>	1199
Paediatric Oncology	Prevention of oral mucositis in paediatric patients treated with chemotherapy: a randomised crossover trial comparing two protocols of oral care <i>K.K.F. Cheng, A.M. Chang and M.P. Yuen</i>	1208
	A survey of current practice with regard to oral care for children being treated for cancer <i>A.M. Glenney, F. Gibson, E. Auld, S. Coulson, J.E. Clarkson, J.V. Craig, O.B. Eden, H.V. Worthington, B. Pizer on behalf of the UKCCSG-PONF Mouth Care Group</i>	1217
Epidemiology and Cancer Prevention	Detection of cervical precancer and cancer in a hospital population: benefits of testing for human papillomavirus <i>V. Dalstein, D. Riethmuller, J.L. Sautière, J.L. Prétet, B. Kantelip, J.P. Schaal and C. Mougin</i>	1225
	Can the survival difference between breast cancer patients in Denmark and Sweden 1989 and 1994 be explained by patho-anatomical variables?—A population-based study <i>L.H. Christensen, G. Engholm, J. Ceberg, S. Hein, R. Perfekt, U.B. Tange, M. Andersson, H.T. Mouridsen, T. Möller and H.H. Storm</i>	1233

List of Contents

	Fiver change in statistical designs of phase II trials published in leading cancer journals <i>S. Thezenas, J. Duffour, S. Culine and A. Kramar</i>	1244
	Reduced breast cancer risk with increasing serum folate in a case-control study of the C677T genotype of the methylenetetrahydrofolate reductase gene <i>J. Beilby, D. Ingram, R. Hähnel and E. Rossi</i>	1250
Experimental Oncology	Molecular analysis of the putative tumour-suppressor gene <i>EXTL1</i> in neuroblastoma patients and cell lines <i>D. Mathysen, N. Van Roy, W. Van Hul, G. Laureys, P. Ambros, F. Speleman and W. Wuyts</i>	1255
	Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice <i>Q.G. de Lussanet, R.G.H. Beets-Tan, W.H. Backes-Tan, D.W.J. van der Schaft, J.M.A. van Engelsehoven, K.H. Mayo and A.W. Griffioen</i>	1262
	Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein <i>E.M. Kemper, M. Verheij, W. Boogerd, J.H. Beijnen and O. van Tellingen</i>	1269
	Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts <i>A. Balsari, M. Tortoreto, D. Besusso, G. Petrangolini, L. Sfondrini, R. Maggi, S. Ménard and G. Pratesi</i>	1275
Calendar of Forthcoming Meetings		I
NUMBER 9		
	Ten most popular EJC papers	viii
	This issue's topics (see after contents pages)	ix
News		1283
Editorial Comment		
	Controversial effect of epoetin in cancer: grounds for a translational research exercise? <i>G. Apolone</i>	1289
Reviews		
	Monoclonal antibodies in the treatment of colorectal cancer <i>M.L. Veronese and P.J. O'Dwyer</i>	1292
	Angiogenesis of gastrointestinal tumours and their metastases – a target for intervention? <i>G. Garcea, T.D. Lloyd, A. Gescher, A.R. Dennison, W.P. Steward and D.P. Berry</i>	1302
Clinical Oncology		
	An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis <i>A.M.L. Oude Lashof, R. De Bock, R. Herbrecht, B.E. de Pauw, V. Krcmery, M. Aoun, M. Akova, J. Cohen, H. Siffrerová, M. Egyed, M. Ellis, A. Marinus, R. Sylvester and B.J. Kullberg for the EORTC Invasive Fungal Infections Group</i>	1314
	Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease <i>S. Ahmed, S.J. Kussick, A.K. Siddiqui, T.A. Bhuiya, A. Khan, S. Sarewitz, H. Steinberg, C.P. Sison and K.R. Rai</i>	1320

	A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours <i>J.-Y. Blay, A. Le Cesne, J. Verweij, M. Scurr, C. Seynaeve, S. Bonvalot, P. Hogendoorn, J. Jimeno, V. Evrard, M. van Glabbeke and I. Judson</i>	1327
	RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group <i>C.J.A. Punt, M.J.A. de Jonge, S. Monfardini, G. Daugaard, W. Fiedler, B. Baron, D. Lacombe and P. Fumoleau</i>	1332
Paediatric Oncology		
	Economic evaluation of treatments for cancer in childhood <i>R.D. Barr, D. Feeny and W. Furlong</i>	1335
	Acute neurotoxicity in children with advanced stage B-non-Hodgkin's lymphoma and B-acute lymphoblastic leukaemia treated with the United Kingdom children cancer study group 9002/9003 protocols <i>A. Atra, C.R. Pinkerton, E. Bouffet, A. Norton, R. Hobson, J.D. Imeson, M. Gerrard on behalf of the United Kingdom Children Cancer Study Group</i>	1346
Epidemiology and Cancer Prevention		
	Increasing incidence rates of childhood malignant diseases in Sweden during the period 1960–1998 <i>A.C. Dreifaldt, M. Carlberg and L. Hardell</i>	1351
	Up-to-date long-term survival of cancer patients: an evaluation of period analysis on Swedish Cancer Registry data <i>M. Talbäck, M. Stenbeck and M. Rosén</i>	1361
Experimental Oncology		
	Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours <i>D. Mennerich, A. Vogel, I. Klamann, E. Dahl, R.B. Lichtner, A. Rosenthal, H.-D. Pohlenz, K.-H. Thierauch and A. Sommer</i>	1373
	Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A <i>G. Sava, F. Frausin, M. Cocchietto, F. Vita, E. Podda, P. Spessotto, A. Furlani, V. Scarcia and G. Zabucchi</i>	1383
	Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone <i>A. Nagler, M. Ohana, O. Shibolet, M.Y. Shapira, R. Alper, I. Vlodavsky, M. Pines and Y. Ilan</i>	1397
	Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies <i>K.T. Christov, R.C. Moon, D.D. Lantvit, C.W. Boone, G.J. Kelloff, V.E. Steele, R.A. Lubet and J.M. Pezzuto</i>	1404
	Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2 <i>A. Safwat, N. Aggerholm, I. Roitt, J. Overgaard and M. Hokland</i>	1412
	Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas <i>E. Ryschich, G. Huszty, H.P. Knaebel, M. Hartel, M.W. Büchler and J. Schmidt</i>	1418
	Disturbed melanin synthesis and chronic oxidative stress in dysplastic naevi <i>S. Pavel, F. van Nieuwpoort, H. van der Meulen, C. Out, K. Pizinger, P. Cetkovská, N.P.M. Smit and H.K. Koerten</i>	1423
	Tumour seeding in peritoneal wound sites in relation to growth-factor expression in early granulation tissue <i>S. Zeamari, E. Roos and F.A. Stewart</i>	1431

List of Contents

	Sodium butyrate induces apoptosis in human hepatoma cells by a mitochondria/caspase pathway, associated with degradation of β -catenin, pRb and Bcl-X _L <i>S. Emanuele, A. D'Anneo, G. Bellavia, B. Vassallo, M. Lauricella, A. De Blasio, R. Vento and G. Tesoriere</i>	1441
Letters		
	A comment on "Douglas House: a 'respite' for young people" <i>A.L. Appleton</i>	1453
	Unknown primary melanoma <i>V. de Giorgi, M. Stante and P. Carli</i>	1454
	Imatinib mesylate in patients with metastatic gastrointestinal stromal tumour relapsing after hepatic transplantation <i>E. Bompas, O. Boillot, P.-P. Bringuier, J. Dumortier and J.-Y. Blay</i>	1456
Calendar of Forthcoming Meetings		I
NUMBER 10		
News		1459
Editorial Comment		
	Langerhans cell histiocytosis: portrait of a disease as a rare tumour <i>J. Donadieu</i>	1465
Reviews		
	Langerhans cell histiocytosis in adults: more questions than answers? <i>M. Aricò</i>	1467
	Systemic therapy for advanced hepatocellular carcinoma: a review <i>A.K. Nowak, P.K.H. Chow and M. Findlay</i>	1474
Clinical Oncology		
	Expression of HER2 and its association with AP-2 in breast cancer <i>J. Pellikainen, A. Naukkarinen, K. Ropponen, J. Rummukainen, V. Kataja, J. Kellokoski, M. Eskelinen, V.-M. Kosma</i>	1485
	Prognostic impact of the early detection of metachronous contralateral breast cancer <i>S. Ciatto, M. Guido and Z. Marco</i>	1496
	Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy <i>A. Vincent-Salomon, A. Rousseau, M. Jouve, P. Beuzeboc, B. Sigal-Zafrani, P. Fréneaux, C. Rosty, C. Nos, F. Campana, J. Klijanienko, A. Al Ghuzlan and X. Sastre-Garau</i>	1502
	Psychological factors and patient delay in patients with head and neck cancer <i>D.M. Tromp, X.D.R. Brouha, J.R.J. De Leeuw, G.J. Hordijk and J.A.M. Winnubst</i>	1509
	Locoregional effects of pegylated liposomal doxorubicin (Caelyx®) in irradiated area: a phase I–II study in patients with recurrent squamous cell carcinoma of the head and neck <i>S. Faivre, H. Alsabe, L. Djafari, F. Janot, M. Julieron, C. Domenge, K. Djazouli, J.-P. Armand, B. Lubinski, E. Raymond</i>	1517
Paediatric Oncology		
	Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie <i>I. Aerts, H. Pacquement, F. Doz, V. Mosseri, L. Desjardins, X. Sastre, J. Michon, J. Rodriguez, P. Schlienger, J.-M. Zucker, E. Quintana</i>	1522

Epidemiology and
Cancer Prevention

Hepatocellular carcinoma in the Netherlands incidence, treatment and survival patterns <i>C. Verhoef, O. Visser, R.A. de Man, J.H.W. de Wilt, J.N.M. Ijzermans and M.L.G. Janssen-Heijnen</i>	1530
Monoclonal proteinaemia and solid tumours <i>C.G. Schaar, S. Snijder, M.J. Oostindier, F.R. Rosendaal, R. Willemze and J.C. Kluin-Nelemans</i>	1539
Staging in patients with locoregionally recurrent breast cancer: current practice and prospects for positron emission tomography <i>F.J. van Oost, J.J.M. van der Hoeven, O.S. Hoekstra, A.C. Voogd, J.W.W. Coebergh and L.V. van de Poll-Franse</i>	1545

Experimental
Oncology

<i>In vivo</i> and <i>in vitro</i> evaluation of erianin, a novel anti-angiogenic agent <i>Y.-Q. Gong, Y. Fan, D.-Z. Wu, H. Yang, Z.-B. Hu and Z.-T. Wang</i>	1554
The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine <i>T. Nishina, I. Hyodo, J. Miyaike, T. Inaba, S. Suzuki and Y. Shiratori</i>	1566
Positive interactive radiosensitisation <i>in vitro</i> with the combination of two nucleoside analogues, (E)-2'-deoxy-2'-(fluoromethylene) cytidine and iododeoxyuridine <i>P.A. Coucke, E. Cottin, D. Azria, P. Martineau, F. Adamer, L.A. Decosterd, F. Buchegger and H.P. Do</i>	1572
Abnormal Fhit protein expression and high frequency of microsatellite instability in sporadic colorectal cancer <i>L. Sarli, L. Bottarelli, C. Azzoni, N. Campanini, G. Di Cola, G. Bader, D. Iusco, C. Salvemini, G. Caruso, E. Donadei, S. Pizzi, T. D'Adda, C. Renato, L. Roncoroni and C. Bordi</i>	1581
Predicting non-small cell lung cancer expression of epidermal growth factor receptor and matrix metalloproteinase 9 from immunohistochemical staining of diagnostic biopsy samples <i>L. Ferrigan and W.A.H. Wallace</i>	1589
Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice <i>K. Flatmark, G.M. Mølandsmo, M. Martinsen, H. Rasmussen and Ø. Fodstad</i>	1593
Truncated mouse adenomatous polyposis coli reduces connexin32 content and increases matrilysin secretion from Paneth cells <i>T. Husøy, H.B. Ølstørn, H.K. Knutsen, E.M. Løberg, V. Cruciani, S.-O. Mikalsen, I.L. Goverud and J. Alexander</i>	1599
Regulation of vascular endothelial growth factor (VEGF)-C and VEGF-D expression by the organ microenvironment in human colon carcinoma <i>S. Onogawa, Y. Kitadai, S. Tanaka, T. Kuwai, T. Kuroda and K. Chayama</i>	1604
Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression <i>A.M. Troy, K. Sheahan, H.E. Mulcahy, M.J. Duffy, J.M.P. Hyland and D.P. O'Donoghue</i>	1610
Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer <i>K. Takenaka, S. Ishikawa, Y. Kawano, K. Yanagihara, R. Miyahara, Y. Otake, Y. Morioka, C. Takahashi, M. Noda, H. Wada and F. Tanaka</i>	1617
Analysis of chromosomes 3, 7, X and the EGFR gene in uterine cervical cancer progression <i>R. Marzano, G. Corrado, R. Merola, C. Sbiroli, F. Guadagni, E. Vizza, F. Del Nonno, M. Carosi, M. Galati M, I. Sperduti and A.M. Cianciulli</i>	1624

Letter		
	Kaposi's sarcoma in Vaud and Neuchatel, Switzerland, 1978–2002 <i>F. Levi, L. Randimbison, V.-C. Te, S. Franceschi and C. La Vecchia</i>	1630
Calendar of Forthcoming Meetings		I
	NUMBER 11	
	This issue's topics (see after contents pages)	
News		1635
Editorial Comment		
	Use of imaging to detect recurrent cancer: How far should we go? <i>S.J. Gwyther</i>	1641
Position Paper		
	Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment <i>P.C.W. Hogendoorn, F. Collin, S. Daugaard, A. P. D. Tos, C. Fisher, U. Schneider, R. Sciort, On behalf of the Pathology and Biology Subcommittee of the EORTC Soft Tissue and Bone Sarcoma Group</i>	1644
Reviews		
	Follicular-cell derived thyroid cancer in children <i>S. Lebourneux, E. Baudin, D.W. Hartl, J.-P. Travagli and M. Schlumberger</i>	1655
	Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression <i>A. Mantovani, P. Allavena and A. Sica</i>	1660
Clinical Oncology		
	Double-reading of plain radiographs – no benefit with regard to earliness of diagnosis of cancer recurrence: a randomised follow-up study <i>R. Järvenpää, K. Holli and M. Hakama</i>	1668
	Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863 <i>F. Ataman, A. Zurlo, X. Artignan, G. van Tienhoven, L. E. Blank, P. Warde, J. B. Dubois, W. Jeanneret, F. Keuppens, J. Bernier, A. Kuten, L. Collette, M. Pierart and M. Bolla</i>	1674
	Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial <i>M. Reni, W. Mason, F. Zaja, J. Perry, E. Franceschi, D. Bernardi, S. Dell'Oro, C. Stelitano, M. Candela, A. Abbadessa, A. Pace, R. Bordonaro, G. Latte, E. Villa and A.J.M. Ferreri</i>	1682
	Fatigue and psychological distress – exploring the relationship in women treated for breast cancer <i>B. Bennett, D. Goldstein, A. Lloyd, T. Davenport and I. Hickie</i>	1689
	Quality of life and stress response symptoms in long-term and recent spouses of testicular cancer survivors <i>M.A. Tuinman, J. Fleer, H.J. Hoekstra, D. Th. Sleijfer and J.E.H.M. Hoekstra-Weebers</i>	1696
	Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer <i>I.J. Diehl, J.-J. Body, M.R. Lichinitser, E.D. Kreuser, W. Dornoff, V.A. Gorbunova, M. Budde, B. Bergström, The MF 4265 Study Group</i>	1704
	Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study <i>N.I. Weijl, T.J. Elsendoorn, E.G.W.M. Lentjes, G.D. Hopman, A. Wipkink-Bakker, A.H. Zwinderman, F.J. Cleton and S. Osanto</i>	1713

	Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review <i>F. Ataman, P. Poortmans, R. Stupp, B. Fisher and R.-O. Mirimanoff</i>	1724
	Predictors of non-sentinel lymph node metastasis in breast cancer patients <i>A. Goyal, A. Douglas-Jones, R.G. Newcombe, R.E. Mansel, On behalf of the ALMANAC Trialists Group</i>	1731
	A survey of surgical management of the axilla in UK breast cancer patients <i>M.S. Gaston and J.M. Dixon</i>	1738
Paediatric Oncology		
	Frequent adverse events after treatment for childhood-onset differentiated thyroid carcinoma: a single institute experience <i>H.M. van Santen, D.C. Aronson, T. Vulsma, R.F.H.M. Tummers, M.M. Geenen, J.J.M. de Vijlder and C. van den Bos</i>	1743
Epidemiology and Cancer Prevention		
	<i>Helicobacter pylori</i> -CagA seropositivity and nitrite and ascorbic acid food intake as predictors for Gastric Cancer <i>L. López-Carrillo, J. Torres-López, M. Galván-Portillo, L. Muñoz and M. López-Cervantes</i>	1752
Experimental Oncology		
	Lethal synergistic effect of cigarette smoke and saliva in an <i>in vitro</i> model: does saliva have a role in the development of oral cancer? <i>O. Hershkovich, J. Oliva and R.M. Nagler</i>	1760
	The effects of lycopene on the proliferation of human breast cells and <i>BRCA1</i> and <i>BRCA2</i> gene expression <i>N. Chalabi, L. Le Corre, J.-C. Maurizis, Y.-J. Bignon and D.J. Bernard-Gallon</i>	1768
	Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24 ⁺ non-small cell lung cancer patients <i>H. Shomura, S. Shichijo, N. Komatsu, S. Matsueda, T. Mine, T. Rikimaru, Y. Sato, S. Todo and K. Itoh</i>	1776
	Midkine promoter-driven suicide gene expression and -mediated adenovirus replication produced cytotoxic effects to immortalised and tumour cells <i>L. Yu, K. Hamada, M. Namba, K. Kadomatsu, T. Muramatsu, S. Matsubara and M. Tagawa</i>	1787
Letter		
	Cervical cancer in a female-to-male trans-sexual <i>D. Driák and M. Šamudovský</i>	1795
Calendar of Forthcoming Meetings		I
NUMBER 12		
	This issue's topics (see after contents pages)	
News		1797
Editorial Comments		
	Old and new markers for breast cancer prognosis: the need for integrated research on quantitative issues <i>E. Biganzoli and P. Boracchi</i>	1803

	Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design? <i>J.-M. Xu, A. Paradiso and H.L. McLeod</i>	1807
Statement		
	The Hamburg statement: the partnership driving the European agenda on breast cancer <i>J. Jassem, M. Buchanan, F. Jänicke, M. Baum, L. Cataliotti, S. Kyriakides, M. Piccart, E.J.T. Rutgers and A. Costa</i>	1810
Reviews		
	Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives <i>J. Rothbarth, R.A.E.M. Tollenaar, J.H.M. Schellens, J.W.R. Nortier, L.J.S. Kool, P.J.K. Kuppen, G.J. Mulder and C.J.H. van de Velde</i>	1812
	Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? <i>A.M.M. Eggermont and J.M. Kirkwood</i>	1825
Clinical Oncology		
	“Good Old” clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers <i>P. Edén, C. Ritz, C. Rose, M. Fernö and C. Peterson</i>	1837
	Impact of surgical staging in patients with macroscopic “stage I” ovarian borderline tumours: analysis of a continuous series of 101 cases <i>S. Camatte, P. Morice, A. Thoury, V. Fourchotte, P. Pautier, C. Lhomme, P. Duvillard and D. Castaigne</i>	1842
	Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist’s perspective <i>O. Belvedere, A. Minisini, M. Ramello, A. Sobrero and F. Grossi</i>	1850
	LH-RH agonists offer very good protection against the adverse gynaecological effects induced by tamoxifen <i>M. Berlière, C. Galant, G. Marques, Ph. Piette, L. Duck, L. Fellah, J. Donnez and J.P. Machiels</i>	1855
	Quality of life after palliative treatment for oesophageal carcinoma – a prospective comparison between stent placement and single dose brachytherapy <i>M.Y.V. Homs, M.-L. Essink-Bot, G.J.J.M. Borsboom, E.W. Steyerberg, P.D. Siersema for the Dutch SIREC Study Group</i>	1862
	Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma <i>D.I. Jodrell, T.R.J. Evans, W. Steward, D. Cameron, J. Prendiville, C. Aschele, C. Noberasco, M. Lind, J. Carmichael, N. Dobbs, G. Camboni, B. Gatti and F. De Braud</i>	1872
Paediatric Oncology		
	Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group <i>L. Sung, J.R. Anderson, S.S. Donaldson, S.L. Spunt, W.M. Crist and A.S. Pappo</i>	1878
Paediatric Update		
	European collaboration in trials of new agents for children with cancer <i>S. Ablett, F. Doz, B. Morland, G. Vassal, On behalf of the New Agents Group of UKCCSG and Pharmacology Group of the SFOP</i>	1886
Commentary		
	Commentary on “European collaboration in trials of new agents for children with cancer” by Ablett <i>et al.</i> <i>M.A. Smith and B.D. Anderson</i>	1893

Epidemiology and
Cancer PreventionExperimental
Oncology

Letter

Calendar of
Forthcoming
Meetings

Announcement 1896

E-Cadherin (*CDH1*) and *p53* rather than *SMAD4* and *Caspase-10* germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients
C. Oliveira, P. Ferreira, S. Nabais, L. Campos, A. Ferreira, L. Cirnes, C. C. Alves, I. Veiga, M. Fragoso, F. Regateiro, L.M. Dias, H. Moreira, G. Suriano, J.C. Machado, C. Lopes, S. Castedo, F. Carneiro and R. Seruca

Expression of hypoxia-inducible factor (HIF)-1 α is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma
S. Kimura, Y. Kitadai, S. Tanaka, T. Kuvvai, J. Hihara, K. Yoshida, T. Toge and K. Chayama

An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole
J.S. Tobias and A. Howell

I

NUMBER 13

Special Issue on Cancer Research: Back to the Future*Guest Editor: John Smyth*

This issue's topics
 (see after contents pages)

40 Years on – dreams, realities and appropriate optimism
J.F. Smyth

Action du Natulan dans 94 cas de tumeurs solides
Y. Kenis, J. De Smedt and H.J. Tagnon

Procarbazine in haematology: an old drug with a new life?
M. Massoud, J.P. Armand and V. Ribrag

The enhancement of the after effect of ionizing radiation by a cytotoxic methylhydrazine derivative
K. Berneis, W. Bollag, M. Kofler and H. Lüthy

The emerging role of reactive oxygen species in cancer therapy
M.F. Renschler

DNA content of tumours
 Cytophotometric measurements
W. Sandritter

Interpretation with hindsight
J. Ansell

The role of chromosomes in the characterisation of human neoplasms
D.T. Hughes

Understanding cancer at the chromosome level: 40 years of progress
S. Debernardi, D. Lillington and B.D. Young

List of Contents

Chemotherapy and surgery of spontaneous tumors of mice <i>S.R. Humphreys, N. Mantel and A. Goldin</i>	1968
Forty years of cancer modelling in the mouse <i>G.L. Hirst and A. Balmain</i>	1974
Quantitative aspects of the storage of bone marrow cells for transplantation <i>L.M. van Putten</i>	1981
The happy destiny of frozen haematopoietic stem cells: from immature stem cells to mature applications <i>E.G.E. de Vries, E. Vellenga, J.C. Kluin-Nelemans and N.H. Mulder</i>	1987
Viruses and tumours <i>R.J.C. Harris</i>	1993
Viruses and tumours – an update <i>S.J. Talbot and D.H. Crawford</i>	1998

NUMBER 14

News	This issue's topics (see after contents pages)	2007
Editorial Comments	Targeting the IGF-1 receptor: from rags to riches <i>R. Baserga</i>	2013
	Targeted therapy – How successful has it been? <i>Ch. Dittrich</i>	2016
Reviews	Sentinel node biopsy in gastrointestinal-tract cancer <i>P.M. Schlag, A. Bembek and T. Schulze</i>	2022
	The treatment of cancer in Greek antiquity <i>A. Karpozilos and N. Pavlidis</i>	2033
	Complementary and alternative medical therapies for children with cancer <i>K.M. Kelly</i>	2041
Clinical Oncology	A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours <i>U. Keilholz, R. Schuster, A. Schmittel, N. Bechrakis, J. Siehl, M.H. Foerster and E. Thiel</i>	2047
	Woman feels breast lump – surgeon cannot: the role of ultrasound in arbitration <i>J.A. Cid, R.S. Rampaul, I.O. Ellis, A.R.M. Wilson, H.C. Burrell, A.J. Evans, R.W. Blamey and R.D. Macmillan</i>	2053
	Psychological distress in women at increased risk for breast cancer: the role of risk perception <i>S. van Dooren, A.J. Rijnsburger, C. Seynaeve, H.J. Duivenvoorden, M.-L. Essink-Bot, M.M.A. Tilanus-Linthorst, H.J. de Koning and A. Tibben</i>	2056
	The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood–testis barrier and in primary testicular tumours <i>J. Bart, H. Hollema, H.J.M. Groen, E.G.E. de Vries, N.H. Hendrikse, D.T. Sleijfer, T.D. Wegman, W. Vaalburg and W.T.A. van der Graaf</i>	2064
	Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer <i>E. Guardiola, F. Peyrade, L. Chaigneau, D. Cupissol, X. Tchiknavorian, E. Bompas, A. Madroszyk, P. Ronchin, M. Schneider, J.P. Bleuze, J.Y. Blay and X. Pivrot</i>	2071

	Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group <i>R.E.N. Van Rijswijk, K. Jeziorski, D.J. TH. Wagener, J.-L. Van Laethem, S. Reuse, B. Baron, J. Wils for the EORTC Gastrointestinal Tract Cancer Co-operative Group</i>	2077
Paediatric Oncology		
	Central nervous system imaging in childhood leukaemia <i>L. Porto, M. Kieslich, D. Schwabe, F.E. Zanella and H. Lanfermann</i>	2082
Paediatric Update		
	New technology for radiotherapy in paediatric oncology <i>F. Saran</i>	2091
Commentary		
	New technologies in radiation oncology: opportunities, caveats and the way forward Commentary on New technology for radiotherapy in paediatric oncology by Dr. Frank Saran <i>C.R. Freeman</i>	2106
Epidemiology and Cancer Prevention		
	Announcement	2108
	Constipation, laxative use and risk of colorectal cancer: The Miyagi Cohort Study <i>T. Watanabe, N. Nakaya, K. Kurashima, S. Kuriyama, Y. Tsubono and I. Tsuji</i>	2109
	Process indicators from ten centres in the Finnish breast cancer screening programme from 1991 to 2000 <i>T. Sarkeala, A. Anttila, H. Forsman, T. Luostarinen, I. Saarenmaa and M. Hakama</i>	2116
Experimental Oncology		
	Announcement	2126
	Identification of cytochrome P450 enzymes in human colorectal metastases and the surrounding liver: a proteomic approach <i>C.S. Lane, S. Nisar, W.J. Griffiths, B.J. Fuller, B.R. Davidson, J. Hewes, K.J. Welham and L.H. Patterson</i>	2127
	Adenoviral-mediated Gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice <i>K. Ueda, M. Iwahashi, I. Matsuura, M. Nakamori, M. Nakamura, T. Ojima, T. Naka, K. Ishida, K. Matsumoto, T. Nakamura and H. Yamaue</i>	2135
	Aberrant expression, processing and degradation of dystroglycan in squamous cell carcinomas <i>J. Jing, C.F. Lien, S. Sharma, J. Rice, P.A. Brennan and D.C. Górecki</i>	2143
	Linkage between androgen receptor gene CAG trinucleotide repeat length and testicular germ cell cancer histological type and clinical stage <i>A. Giwercman, K.B. Lundin, J. Eberhard, O. Ståhl, M. Cwikiel, E. Cavallin-Ståhl and Y.L. Giwercman</i>	2152
	Plasma TIMP-1 in patients with colorectal adenomas: a prospective study <i>M.N. Holten-Andersen, C. Fenger, H.J. Nielsen, A.-S.S. Rasmussen, I.J. Christensen, N. Brønner and O. Kronborg</i>	2159
	Black tea polyphenol theaflavins inhibit aromatase activity and attenuate tamoxifen resistance in HER2/neu-transfected human breast cancer cells through tyrosine kinase suppression <i>T.-D. Way, H.-H. Lee, M.-C. Kao and J.-K. Lin</i>	2165
	5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer <i>C. Tzao, H.-Y. Tsai, J.-T. Chen, C.-Y. Chen and Y.-C. Wang</i>	2175

Calendar of
Forthcoming
Meetings

I

NUMBER 15

	Ten most popular <i>EJC</i> papers	x
	This issue's topics (see after contents page)	
News		2185
Editorial Comment		
	Early mortality rates: a tool for phase III trials or for changing standard practice? <i>J. Verweij and J. Smyth</i>	2190
Position Paper		
	A new international framework for palliative care <i>S.H. Ahmedzai, A. Costa, C. Blengini, A. Bosch, J. Sanz-Ortiz, V. Ventafridda and S.C. Verhagen, on behalf of the international working group convened by European School of Oncology</i>	2192
Guidelines		
	EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer <i>C. Bokemeyer, M.S. Aapro, A. Courdi, J. Foubert, H. Link, A. Österborg, L. Repetto and P. Soubeyran</i>	2201
Review		
	The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications <i>A.M. Burger and A.K. Seth</i>	2217
Clinical Oncology		
	Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital <i>O. Katopodis, P. Ross, A.R. Norman, J. Oates and D. Cunningham</i>	2230
	Change in histological grade in locally recurrent soft tissue sarcomas <i>P.C. Ferguson, N. Deshmukh, A. Abudu, S.R. Carter, R.M. Tillman and R.J. Grimer</i>	2237
	French version of FACT-G: validation and comparison with other cancer-specific instruments <i>T. Conroy, M. Mercier, J. Bonnetterre, E. Luporsi, J.L. Lefebvre, M. Lapeyre, M. Puyraveau and S. Schraub</i>	2243
	Risk factors for catheter-related thrombosis in cancer patients <i>M.E.T. Tesselaar, J. Ouwkerk, M.A. Nooy, F.R. Rosendaal and S. Osanto</i>	2253
	Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer <i>J.M. Blazeby, T. Conroy, A. Bottomley, C. Vickery, J. Arraras, O. Sezer, J. Moore, M. Koller, N.S. Turhal, R. Stuart, E. van Cutsem, S. D'haese and C. Coens, On behalf of the European Organisation for Research and Treatment of Cancer Gastrointestinal and Quality of Life Group</i>	2260
	Protein kinase C alpha expression in normal breast, ductal carcinoma <i>in situ</i> and invasive ductal carcinoma <i>P.D. Ainsworth, J.H.R. Winstanley, J.M. Pearson, H.M. Bishop and D.R. Garrod</i>	2269
Paediatric Oncology		
	Phase II study of high-dose cyclophosphamide in relapsing and/or resistant hepatoblastoma in children: a study from the SIOPEL group <i>W.D. Cacciavillano, L. Brugières, M. Childs, E. Shafford, P. Brock, J. Pritchard, R. Mailbach, M. Scopinaro and G. Perilongo</i>	2274

List of Contents

	Symptom interval in young people with bone cancer	2280
	<i>S. Goyal, J. Roscoe, W.D.J. Ryder, H.R. Gattamaneni and T.O.B. Eden</i>	
	Methotrexate inhibits the glyoxalase system <i>in vivo</i> in children with acute lymphoid leukaemia	2287
	<i>K. Bartyik, S. Turi, F. Orosz and E. Karg</i>	
Epidemiology and Cancer Prevention		
	The European cancer anaemia survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients	2293
	<i>H. Ludwig, S. Van Belle, P. Barrett-Lee, G. Birgegård, C. Bokemeyer, P. Gascón, P. Kosmidis, M. Krzakowski, J. Nortier, P. Olmi, M. Schneider and D. Schrijvers</i>	
	Standard cancer patient population for age standardising survival ratios	2307
	<i>I. Corazzari, M. Quinn and R. Capocaccia</i>	
	An alternative approach to age adjustment of cancer survival rates	2317
	<i>H. Brenner, V. Arndt, O. Gefeller and T. Hakulinen</i>	
Experimental Oncology		
	Announcement	2323
	Galectin-3 – an emerging prognostic indicator in advanced head and neck carcinoma	2324
	<i>J. Plzák, J. Betka, K. Smetana, M. Chovanec, H. Kaltner, S. André, R. Kodet and H.-J. Gabius</i>	
	Stage-specific inhibition of mammary carcinogenesis by 1 α -hydroxyvitamin D5	2331
	<i>R.G. Mehta</i>	
Calendar of Forthcoming Meetings		I
NUMBER 16		
	This issue's topic (see after contents pages)	
News		2339
Editorial Comments		
	Chemotherapy for advanced lung cancer	2345
	<i>F. Blackhall and N. Thatcher</i>	
	Intensity Modulated Radiation Therapy	2349
	<i>V. Murthy and A. Horwich</i>	
	Best practice in assessing ototoxicity in children with cancer	2352
	<i>R. Skinner</i>	
Current Perspective		
	Cutaneous malignant melanoma in Europe	2355
	<i>E. de Vries and J. W. Coebergh</i>	
	Perspectives in melanoma prevention: the case of sunbeds	2367
	<i>P. Autier</i>	
Reviews		
	Thalidomide in solid tumours: the resurrection of an old drug	2377
	<i>S. Sleijfer, W.H.J. Kruit and G. Stoter</i>	

	Multistep laryngeal carcinogenesis helps our understanding of the field cancerisation phenomenon: a review <i>G. Almadori, F. Bussu, G. Cadoni, J. Galli, M. Rigante, A. Artuso and M. Maurizi</i>	2383
Clinical Oncology		
	Independent prognostic factors for distant metastases and survival in patients with primary uveal melanoma <i>A. Schmitt, N.E. Bechrakis, P. Martus, D. Mutlu, C. Scheibenbogen, N. Bornfeld, M.H. Foerster, E. Thiel and U. Keilholz</i>	2389
	Surgery and outcomes of ductal carcinoma <i>in situ</i> of the breast: a population-based study in Australia <i>A. Kricker and B. Armstrong</i>	2396
	Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer <i>L. Fallowfield, R. McGurk and M. Dixon</i>	2403
	High conformality radiotherapy in Europe: thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991 <i>F. Ataman, P. Poortmans, J.B. Davis, J. Bernier, J.-Y. Giraud, V.E. Kouloulis, M. Pierart and M. Bolla</i>	2411
	Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers <i>B. Linderholm, E. Karlsson, S. Klaar, T. Lindahl, A.-L. Borg, G. Elmberger and J. Bergh</i>	2417
	Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial <i>C. Gridelli, C. Manegold, P. Mali, M. Reck, L. Portalone, O. Castelnau, R. Stahel, D. Betticher, M. Pless, J. Terrassa Pons, D. Aubert, J.-P. Burillon, Y. Parhier and F. De Marinis</i>	2424
	Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study <i>A. Schneeweiss, J. Huober, H.-P. Sinn, D. von Fournier, C. Rudlowski, F. Beldermann, K. Krauss, E. Solomayer, R. Hamerla, D. Wallwiener and G. Bastert</i>	2432
	Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18 <i>J.M. Blazeby, E. Currie, B.C.Y. Zee, W.-C. Chie, R.T. Poon and O.J. Garden, On behalf of the EORTC</i>	2439
Paediatric Oncology		
	Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose <i>Y. Li, R.B. Womer and J.H. Silber</i>	2445
	Port-A-Cath infections in children with cancer <i>H. Hengartner, C. Berger, D. Nadal, F.K. Niggli and M.A. Grotzer</i>	2452
Paediatric Update		
	Inherited cancer in children: practical/ethical problems and challenges <i>M. Tischkowitz and E. Rosser</i>	2459
Commentary		
	Genetics and childhood cancer. Commentary on: Inherited cancer in Children: practical / ethical problems and Challenges <i>J.A. Ross</i>	2471
Epidemiology and Cancer Prevention		
	Announcement	2473
	A gene-environment interaction between occupation and <i>BRCA1/BRCA2</i> mutations in male breast cancer? <i>D. Palli, G. Masala, R. Mariani-Costantini, I. Zanna, C. Saieva, F. Sera, A. Decarli and L. Ottini</i>	2474

	Familial association of colorectal adenocarcinoma with cancers at other sites <i>K. Hemminki and B. Chen</i>	2480
	The impact of education and occupation on the employment status of cancer survivors <i>T. Taskila-Åbrandt, R. Martikainen, S.V. Virtanen, E. Pukkala, P. Hietanen and M.-L. Lindbohm</i>	2488
	Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases <i>H. Brenner and B. Rachet</i>	2494
	Epidemiological differences for cutaneous melanoma in a relatively dark-skinned caucasian population with chronic sun exposure <i>K. Lasithiotakis, S. Krüger-Krasagakis, D. Ioannidou, I. Padiaditis and A. Tosca</i>	2502
Experimental Oncology	Announcement	2508
	Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy <i>D. Chelouche-Lev, C.P. Miller, C. Tellez, M. Ruiz, M. Bar-Eli and J.E. Price</i>	2509
	Somatic D-loop mitochondrial DNA mutations are frequent in uterine serous carcinoma <i>T. Pejovic, D. Ladner, M. Intengan, K. Zheng, T. Fairchild, D. Dillon, S. Easley, D. Dillon, D. Marchetti, P. Schwartz, S. Lele, J. Costa and K. Odumsi</i>	2519
	Analysis of transcripts from 17p13.3 in medulloblastoma suggests <i>ROX/MNT</i> as a potential tumour suppressor gene <i>A. Cvekl, J. Zavadil, B.K. Birshstein, M.A. Grotzer and A. Cvekl</i>	2525
Erratum	Erratum to “High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as a second-line therapy for metastatic colorectal cancer (FOLFOX 7)” [European Journal of Cancer 37 (2001) 1000–1005] <i>F. Maindrault-Goebl, A. de Gramont, C. Louvet, T. André, E. Carola, M. Mabro, P. Artru, V. Gilles, J.P. Lotz, V. Izrael and M. Krulik</i>	2533
Calendar of Forthcoming Meetings		I

NUMBER 17

Special Issue on Gene Transcription and Cancer, from the Genome Project to Practical Achievements in Diagnosis and Therapy*Guest Editors: M. D'Incalci, R. Dulbecco*

This issue's topic
(see after content page)

Introduction <i>M. D'Incalci and R. Dulbecco</i>	2535
The human genome project and the discovery of genetic determinants of cancer susceptibility <i>R. Taramelli and F. Acquati</i>	2537
Transcription profiling of gene expression in drug discovery and development: the NCI experience <i>E.A. Sausville and S.L. Holbeck</i>	2544
Improving the selectivity of cancer treatments by interfering with cell response pathways <i>G. Damia and M. Brogгинi</i>	2550

List of Contents

Gene expression microarray technologies in the development of new therapeutic agents <i>P.A. Clarke, R. te Poele and P. Workman</i>	2560
Interpretation of expression-profiling results obtained from different platforms and tissue sources: examples using prostate cancer data <i>G. Chiorino, F. Acquadro, M. M. Grand, S. Viscomi, R. Segir, M. Gasparini and P. Dotto</i>	2592
Biomarkers of ovarian tumours <i>A.V. Rapkiewicz, V. Espina, E.F. Petricoin III and L.A. Liotta</i>	2604
Circulating biomarkers from tumour bulk to tumour machinery: promises and pitfalls <i>M. Gion and M.G. Daidone</i>	2613
Genomic and proteomic technologies for individualisation and improvement of cancer treatment <i>J. Wulfskuhle, V. Espina, L. Liotta and E. Petricoin</i>	2623

NUMBER 18

This issue's topics
(see after contents pages)

News	2633
------	------

Editorial Comments

MYCN amplification remains prognostically strong 20 years after its "clinical debut" <i>S.L. Cohn and D.A. Tweddle</i>	2639
Hepatic veno-occlusive disease and portal vein thrombosis; closer than we think? <i>N. Hadzic</i>	2643

Meeting Report

EACR-18: the best of European cancer research <i>V. Jendrossek and R.J. White</i>	2645
--	------

Reviews

Portal vein thrombosis during antineoplastic chemotherapy in children: Report of five cases and review of the literature <i>H. Brisse, D. Orbach, N. Lassau, V. Servois, F. Doz, D. Debray, S. Helfre, O. Hartmann and S. Neuenschwander</i>	2659
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities <i>T. Sørli</i>	2667
Marine pharmacology in 2001–2: antitumour and cytotoxic compounds <i>A.M.S. Mayer and K.R. Gustafson</i>	2676
Contraception for teenagers and young adults with cancer <i>V. Laurence, B.A. Gbolade, S.J. Morgan and A. Glaser</i>	2705

Clinical Oncology

Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer <i>T.A. Martin, G. Watkins, R.E. Mansel and W.G. Jiang</i>	2717
The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study <i>W. Boogerd, M.J. van den Bent, P.J. Koehler, J.J. Heimans, J.J. van der Sande, N.K. Aaronson, A.A.M. Hart, J. Benraadt and Ch. J. Vecht</i>	2726
Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer <i>Ö. U. Ataman, S.M. Bentzen, G.D. Wilson, F.M. Daley, P.I. Richman, M.I. Saunders and S. Dische</i>	2734

	Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status <i>J.M. Dixon, J. Jackson, M. Hills, L. Renshaw, D.A. Cameron, T.J. Anderson, W.R. Miller and M. Dowsett</i>	2742
	Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group Study <i>F. Duffaud, M. Borner, P. Chollet, J.B. Vermorken, J. Bloch, M. Degardin, F. Rolland, C. Ditttrich, B. Baron, D. Lacombe and P. Fumoleau, for the EORTC-New Development Group/New Drug Development program</i>	2748
Paediatric Oncology		
	MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification <i>R. Spitz, B. Hero, M. Skowron, K. Ernestus and F. Berthold</i>	2753
	Low occurrence of familial neuroblastomas and ganglioneuromas in five consecutive GPOH neuroblastoma treatment studies <i>A. Claviez, M. Lakomek, J. Ritter, M. Suttorp, B. Kremens, R. Dickerhoff, D. Harms, F. Berthold and B. Hero</i>	2760
Epidemiology and Cancer Prevention		
	Further clues concerning the aetiology of childhood central nervous system tumours <i>R.J.Q. McNally, R.D. Alston, T.O.B. Eden, A.M. Kelsey and J.M. Birch</i>	2766
	The importance of assessing the readiness to change sun-protection behaviours: a population-based study <i>S. Kristjánsson, H. Ullén and Á. R. Helgason</i>	2773
	Gender and age-related differences in Burkitt lymphoma – epidemiological and clinical data from The Netherlands <i>E.G. Boerma, G.W. van Imhoff, I.M. Appel, N.J.G.M. Veeger, Ph. M. Kluin and J.C. Kluin-Nelemans</i>	2781
	BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study <i>T. Rafnar, K.R. Benediktsdottir, B.J. Eldon, T. Gestsson, H. Saemundsson, K. Olafsson, A. Salvarsdottir, E. Steingrimsdottir and S. Thorlacius</i>	2788
	Sheep and goats: separating cervix and corpus uteri from imprecisely coded uterine cancer deaths, for studies of geographical and temporal variations in mortality <i>A.H. Loos, F. Bray, P. McCarron, E. Weiderpass, M. Hakama and D.M. Parkin</i>	2794
Experimental Oncology		
	Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma <i>A. Faried, M. Sohda, M. Nakajima, T. Miyazaki, H. Kato and H. Kuwano</i>	2804
	Prognostic significance of detecting micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies: lessons from 322 consecutive melanoma patients <i>J. Ulrich, B. Bonnekoh, R. Böckelmann, M. Schön, M.P. Schön, R. Steinke, A. Roessner, U. Schmidt and H. Gollnick</i>	2812
	Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours <i>A. Harder, M. Rosche, D.E. Reuß, N. Holtkamp, K. Uhlmann, R. Friedrich, V.F. Mautner and A. von Deimling</i>	2820
	Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells <i>M.F. Romano, R. Avellino, A. Petrella, R. Bisogni, S. Romano and S. Venuta</i>	2829
	Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab <i>P. Formento, J.-M. Hannoun-Levi, J.-L. Fischel, N. Magne, M.-C. Etienne-Grimaldi and G. Milano</i>	2837

List of Contents

Clinical relevance of thymidylate synthase expression in the signet ring cell histotype component of colorectal carcinoma <i>D. Cabibi, A. Calascibetta, M. Campione, E. Barresi, L. Rausa, G. Dardanoni, F. Aragona and R. Sanguedolce</i>	2845
Noninvasive <i>in vivo</i> whole body luminescent analysis of luciferase labelled orthotopic prostate tumours <i>N. El Hilali, N. Rubio and J. Blanco</i>	2851
Letter	
Letter to the Editor <i>C. Rose</i>	2859
Referees – 2004	2860
List of Contents, Volume 40, 2004	2863
Author Index, Volume 40, 2004	2898
Calendar of Forthcoming Meetings	I

SUPPLEMENT 1

Controversies in Tumor Prevention and Genetics

SUPPLEMENT 2

Of Oxygen, Hemoglobin and Tumor Treatment

Introduction: Of oxygen, hemoglobin, and tumor treatment <i>R. Bugat, M. Freund, J.W.R. Nortier and P. Vaupel</i>	1
Low hemoglobin levels: influence on tumor biology and radiotherapy treatment outcome <i>J. Dunst</i>	3
What is the value of hemoglobin as a prognostic and predictive factor in cancer? <i>S.J.-P. Van Belle</i>	11
Is there a possible survival benefit to increasing hemoglobin levels with epoetin alfa during chemotherapy? <i>M. Aapro, E. Bajetta, M. Freund, T.J. Littlewood, J.W.R. Nortier, B. Rapoport for the Epoetin Alfa Study Group</i>	20
Epoetin alfa has potential efficacy in central nervous system disorders <i>A. Cerami, M. Brines and C. Cerami</i>	29
Strategies for optimizing hemoglobin response in cancer patients: focus on new epoetin alfa dosing regimens <i>P. Sabbatini</i>	36
Summary: Of oxygen, hemoglobin, and tumor treatment <i>R. Bugat and P. Vaupel</i>	41

SUPPLEMENT 3

4th European Breast Cancer Conference

SUPPLEMENT 4

Thoracic Malignancies

New targets and new treatments in non-small cell lung cancer <i>B.E. Johnson</i>	1
The role of imaging in screening, diagnosis and staging of Non-Small Cell Lung Cancer (NSCLC) <i>S.C. Rankin</i>	7
Management of non-small cell lung cancer in elderly patients <i>C. Gridelli, P. Maione, A. Rossi, C. Colantuoni, M.L. Barzelloni, V. Salerno and G. Airoma</i>	15
Status and trends of chemotherapy for advanced NSCLC <i>T. Le Chevalier and J.-C. Soria</i>	26
New perspectives in the management of non-small cell lung cancer (NSCLC): Gefitinib (Iressa, ZD 1839) <i>C. Manegold</i>	34
Management of small cell lung cancer <i>N. Thatcher</i>	40

SUPPLEMENT 5

Ibandronate: Meeting the Needs of Metastatic Bone Disease Today

Bisphosphonates for metastatic bone disease: a therapeutic rationale <i>R. Bell</i>	1
Reducing skeletal complications and bone pain with intravenous ibandronate for metastatic bone disease <i>J.-J. Body</i>	5
Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease <i>B. Leyland-Jones</i>	9
Ibandronate: a well-tolerated intravenous and oral treatment for metastatic bone disease <i>I.J. Diel</i>	13
Oral daily ibandronate: an effective and convenient therapy for skeletal complications in metastatic breast cancer <i>D. Tripathy</i>	17

SUPPLEMENT 6

Major Advances in Oncology: The Clinical Potential of Proteasome Inhibition

Proteasome inhibition as a major advance in oncology <i>B. Coiffier</i>	1
The clinical potential of proteasome inhibition <i>K.C. Anderson</i>	3
Proteasome inhibition: potential benefits in the treatment of cancer <i>S.B. Kaye</i>	7
Bortezomib in multiple myeloma: treatment approach and outcomes <i>J.-L. Harousseau</i>	12
Bortezomib: clinical profile in lymphoproliferative malignancies <i>O.A. O'Connor</i>	18
Clinical potential of proteasome inhibition in solid tumours <i>G. Giaccone</i>	25

SUPPLEMENT 7

Second Clinical Investigators Update Meeting on Gastrointestinal Cancer

Colorectal cancer in 2003: state of the art and new developments <i>E. Diaz-Rubio, J. Dorta and R. Labianca</i>	1
Level of evidence of irinotecan clinical trials and recent data in colorectal cancer <i>C.-H. Köhne</i>	3
Elderly colorectal cancer patients are under treated <i>P. Rougier, E. Mitry, E. Aranda, B. Daniele, R. Labianca and A. Carrato</i>	8
Irinotecan in combination with new agents <i>U. Vanhoefer, P. Rougier, M. Borner, A. Muñoz, J.-L. Van Laethem and A. Sobrero</i>	14
Current surgical strategies for the treatment of colorectal cancer liver metastases <i>R. Adam</i>	21
The role of irinotecan in the treatment of colorectal cancer metastases: surgeons and oncologists in partnership <i>B. Nordlinger, M. Ducreux, H. Wasan and C. Pozzo</i>	27
New approaches for the treatment of colorectal cancer in the adjuvant setting <i>D. Kerr and E. Van Cutsem</i>	34
State of the art treatment for gastric cancer: future directions <i>A. Cervantes, V. Georgoulas and A. Falcone</i>	40
Irinotecan for the treatment of gastric cancer <i>H. Wilke, O. Bouché, P. Rougier and C.-H. Köhne</i>	48
Docetaxel in gastric cancer <i>E. Van Cutsem on behalf of the TAX 325 Study group</i>	52
What have we learned and where are we going in the treatment of colorectal and gastric cancer? <i>E. Van Cutsem, E. Diaz-Rubio and H. Wilke</i>	59

SUPPLEMENT 8

16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

SUPPLEMENT 9

Endocrine Treatment and Prevention of Breast and Gynaecological Cancers

Editorial

Endocrine treatment and prevention of breast and gynaecological cancers <i>P. Neven, I. Vergote, F. De Prins, C. De Rop, W. Tjalma, P. Van Dam and J. Van Ginderachter</i>	1
---	---

Part I: Extended abstracts of invited papers

E1. Endocrine prevention of breast cancer <i>T.J. Powles</i>	15
E2. Tamoxifen use for breast cancer chemoprevention among U.S. women <i>A.N. Freedman, B.I. Graubard, W. McCaskill-Stevens, M.H. Gail and R. Ballard-Barbash</i>	17

E3. Menopausal symptoms and uterine changes in postmenopausal breast cancer patients receiving tamoxifen or third generation aromatase inhibitors <i>L. Morales, P. Neven, D. Timmerman, M.L. Konstantinovic, I. Vergote, M.-R. Christiaens, E. Van Limbergen, C. Weltens, A. Carbonez, S. Van Huffel, L. Ameye and R. Paridaens</i>	19
E4. Tamoxifen and gynaecological side-effects: an update <i>M.Ĵ. Mourits, H. Hollema, P.H. Willemse, E.G. de Vries and A.G. van der Zee</i>	22
E5. Selective oestrogen receptor modulator's (SERM's) added to the list of human carcinogens <i>P.L. Carmichael and Ĵ.C.M. Pole</i>	24
E6. How do we choose candidates for breast cancer prevention? <i>S.R. Goldstein</i>	26
E7. The search for new breast cancer susceptibility genes <i>P. Devilee</i>	29
E8. Prevention of breast and gynaecological tumours when there is a proven genetic risk: a review <i>E. de Jonge</i>	31
E9. Side-effects of tamoxifen and solutions with aromatase inhibitors <i>Ĵ. Cuzick</i>	33
E10. Interpreting the results of the women's health initiative within the context of our current understanding of oestrogen and progesterone action <i>D.P. McDonnell</i>	35
E11. Endocrine resistance in breast cancer – how to overcome it? <i>S.R.D. Johnston</i>	41
E12. Predictors of resistance to hormonal therapy in breast cancer <i>M. Dowsett, L.-A. Martin, S. Johnston and I.E. Smith</i>	43
E13. Oestrogen receptors in metastatic breast cancer <i>S.A.W. Fuqua, T. Hopp and Y. Cui</i>	45
E14. The prognostic and predictive value of the progesterone receptor in women with an oestrogen receptor-positive breast cancer <i>P. Neven, H.Ĵ. Huang, R. Vanspauwen, F. Amant, P. Berteloot, E. Van Limbergen, H. Wildiers, R. Paridaens, M.R. Christiaens and I. Vergote</i>	46
E15. Use of microarray analysis to predict outcome and response in breast cancer patients <i>E.M.Ĵ.Ĵ. Berns</i>	49
E16. Amenorrhoea, aromatase inhibitors, tamoxifen or a combination in premenopausal women <i>R. Ĵakesz</i>	51
E17. Are aromatase inhibitors superior to tamoxifen after the menopause? <i>A.U. Buzdar</i>	54
E18. How important is c-erb B2 or HER-2/neu when deciding on which therapy? <i>B.W. Lisboa and F. Ĵänicke</i>	56
E19. Letrozole: a new partner in the fight against relapses from endocrine-responsive breast cancer <i>M.Ĵ. Piccart, L. Shepherd and P. Goss</i>	58
E20. Neoadjuvant endocrine therapy in breast cancer <i>Ĵ.M. Dixon</i>	60
E21. What is the best therapy for ER-positive breast cancer? <i>Ĵ.G.M. Klijn</i>	62
E22. Fulvestrant in 2004: current and future indications for breast cancer <i>A. Howell</i>	65
E23. Endocrine therapy in metastatic endometrial cancer <i>I. Vergote, F. Amant, P. Neven and P. Berteloot</i>	67

E24. Low-dose intrauterine levonorgestrel release protects the endometrium during oestrogen replacement: an update <i>D. Wildemeersch, S. Weyers, D. Janssens and E. Schacht</i>	70
E25. The tissue-selective mechanism of action of tibolone: breast and endometrium <i>H.J. Kloosterboer</i>	72
E26. Selective oestrogen enzyme modulators (SEEMs) and their effect on the breast and endometrium <i>J.R. Pasqualini and G. Chetrite</i>	74
E27. Tibolone. A viable alternative to hormonal therapy: impact on endometrium <i>J.M. Foidart</i>	78
E28. Breast tolerance, tibolone compared with other hormonal treatments <i>H.L. Olsson</i>	79
E29. Management of the menopause in breast cancer patients <i>S. Rozenberg, C. Antoine, J. Vandromme, B. Carly, A. Pastijn, S. Neusy and F. Liebens</i>	81

Part II: Extended
abstracts of
selected papers

S1. The association between tamoxifen and uterine carcinosarcoma <i>V. Hughes and N. Reed</i>	85
S2. The value of sonohysterography in the prediction of endometrial pathologies in asymptomatic postmenopausal, tamoxifen-treated breast cancer patients <i>O. Markovitch, R. Tepper, R. Aviram, A. Fishman, J. Shapira and I. Cohen</i>	86
S3. p53 mutations in endometrial tumours from tamoxifen-treated women <i>K. Brown, H. Pearson, P. Neven, P.B. Farmer and P.L. Carmichael</i>	87
S4. The TAMARISK-study, a cohort study of the clinico-pathological and molecular characteristics, and the prognosis of uterine malignancies after tamoxifen <i>W.E. Hoogendoorn, H. Hollema, P.M. Nederlof, H.H. van Boven, M.J. Mourits and F.E. van Leeuwen</i>	88
S5. Longterm prognostic value of oestrogen receptor and progesterone receptor in early stage breast cancer <i>C. Collen, C. Fontaine, I. Samijn, G. Vlastos, P. Tai, A. Bretz, G. Cserni, Z.B. Nagy, J. De Greve, G. Storme, and V. Vinh-Hung</i>	89
S6. Association between the progesterone receptor and HER-2/neu in oestrogen receptor positive breast cancer <i>H.-J. Huang, P. Neven, M. Drijkoningen, H. Wildiers, R. Paridaens, E. Van Limbergen, P. Berteloot, F. Amant, I. Vergote and M.R. Christiaens</i>	90
S7. Clinical significance of histone deacetylase 6 expression in breast cancer <i>H. Iwase, H. Yamashita, Y. Omoto, T. Toyama, H. Sugiura, Z. Zhang and S. Hayashi</i>	91
S8. Clinical implications of oestrogenrelated receptor (ERR) expression levels in endometrial cancers <i>J. Fujimoto, Y. Nakagawa, H. Toyoki, H. Sakaguchi and T. Tamaya</i>	92
S9. Conservative management of atypical endometrial hyperplasia and early invasive carcinoma with intrauterine levonorgestrel: a progesterone receptor study <i>W.A.A. Tjalma, D. Janssens, D. Wildemeersch, C. Colpaert and K. Watty</i>	93
S10. Immunohistochemical determination of oestrogen and progesterone receptor positivity in uterine adenosarcoma <i>F. Amant, K. Schurmans, E. Steenkiste, L. Verbist, V.M. Abeler, G. Tulunay, E. de Jonge, L. Massuger, P. Moerman and I. Vergote</i>	95

S11. C-erbB-2 overexpression and amplification in uterine sarcomas <i>V. Vloeberghs, F. Amant, H. Woestenborghs, M. Debiec-Rychter, L. Verbist, P. Moerman and I. Vergote</i>	96
S12. Both mode of detection and hormone replacement therapy affect breast cancer characteristics in postmenopausal women <i>F. Stroef, H.J. Huang, T. Van Mieghem, F. Amant, P. Berteloot, R. Vandebröeck, N. Schockaert, G. Staelens, J. Van den Haute, C. De Rop, J. Vlasselaers, R. Paridaens, C. Van Ongeval, A. Van Steen, I. Vergote, M.R. Christiaens, P. Neven, on behalf of the FGOG's breast group</i>	97
Part III: Invited abstracts	99
Part IV: Posters	105

CONTENTS
Direct

This journal is part of **ContentsDirect**, the *free* alerting service which sends tables of contents by e-mail for Elsevier books and journals. You can register for **ContentsDirect** online at: <http://contentsdirect.elsevier.com>

Indexed/Abstracted in:
Current Contents;
EMBASE/Excerpta Medica;
Index Medicus; MEDLINE;
CABS, BIOSIS Database;
PASCAL-CNRS Database

